Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
94 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06687369 | A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) | active not recruiting | Phase 3 | 726 | mAbxience Research S.L.INDUSTRY | 24 | Sep 10, 2026 | clinicaltrials |
| NCT07760688 | Structured Periprocedural Nursing Interventions in Men Undergoing Transrectal Prostate Biopsy | recruiting | N/A | 120 | University of MostarOTHER | 1 | Aug 12, 2026 |
| NCT03456076 | A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer | active not recruiting | Phase 3 | 257 | Hoffmann-La RocheINDUSTRY | 27 | Jul 15, 2026 | clinicaltrials |
| NCT06153238 | A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma | completed | Phase 1 | 322 | SandozINDUSTRY | 18 | Jul 7, 2026 | clinicaltrials |
| NCT06348199 | A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer | active not recruiting | Phase 3 | 555 | Samsung Bioepis Co., Ltd.INDUSTRY | 14 | Jul 7, 2026 | clinicaltrials |
| NCT04961996 | A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | active not recruiting | Phase 3 | 4,170 | Hoffmann-La RocheINDUSTRY | 54 | Jun 17, 2026 | clinicaltrials |
| NCT02075840 | A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants(ALEX) | completed | Phase 3 | 303 | Hoffmann-La RocheINDUSTRY | 29 | May 29, 2026 | clinicaltrials |
| NCT04824794 | GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 130 | GenmabINDUSTRY | 20 | May 19, 2026 | clinicaltrials |
| NCT04516447 | A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer(MUIR) | recruiting | Phase 1 | 172 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 7 | Apr 7, 2026 | clinicaltrials |
| NCT05907122 | A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma | completed | Phase 3 | 256 | AmgenINDUSTRY | 22 | Mar 27, 2026 | clinicaltrials |
| NCT05415215 | A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer(ProHer) | completed | Phase 3 | 346 | Hoffmann-La RocheINDUSTRY | 17 | Feb 10, 2026 | clinicaltrials |
| NCT06054555 | A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma | active not recruiting | Phase 3 | 633 | AmgenINDUSTRY | 31 | Jan 12, 2026 | clinicaltrials |
| NCT03371017 | A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer(IMpassion132) | completed | Phase 3 | 595 | Hoffmann-La RocheINDUSTRY | 28 | Nov 12, 2025 | clinicaltrials |
| NCT02514447 | Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy | completed | Phase 1 / Phase 2 | 123 | G1 Therapeutics, Inc.INDUSTRY | 8 | Sep 25, 2025 | clinicaltrials |
| NCT06551064 | Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients(Dahlia) | active not recruiting | Phase 1 | 96 | Formycon AGINDUSTRY | 11 | Sep 4, 2025 | clinicaltrials |
| NCT07130916 | A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer | recruiting | Phase 1 | 20 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 3 | Aug 19, 2025 | clinicaltrials |
| NCT05201404 | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis(LIVERATION) | recruiting | Phase 3 | 471 | Can-Fite BioPharmaINDUSTRY | 9 | Apr 29, 2025 | clinicaltrials |
| NCT02807636 | Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma(IMvigor130) | completed | Phase 3 | 1,213 | Hoffmann-La RocheINDUSTRY | 35 | Feb 24, 2025 | clinicaltrials |
| NCT03673306 | Safety of Pregnancy in BRCA Mutated Breast Cancer Patients | completed | — | 4,732 | Jules Bordet InstituteOTHER | 26 | Dec 13, 2024 | clinicaltrials |
| NCT03560531 | A Study of ZN-c5 in Subjects With Breast Cancer | completed | Phase 1 / Phase 2 | 181 | Zeno Alpha Inc.INDUSTRY | 9 | Aug 9, 2024 | clinicaltrials |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)(MODUL) | completed | Phase 2 | 1,044 | Hoffmann-La RocheINDUSTRY | 23 | May 6, 2024 | clinicaltrials |
| NCT01120184 | A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) | completed | Phase 3 | 1,095 | Hoffmann-La RocheINDUSTRY | 38 | Mar 4, 2024 | clinicaltrials |
| NCT03446417 | A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer | completed | Phase 1 | 34 | Zeno Pharmaceuticals, Inc.INDUSTRY | 2 | Jan 25, 2024 | clinicaltrials |
| NCT02617485 | MabionCD20 Compared to MabThera in Lymphoma Patients(MADILYM) | completed | Phase 3 | 143 | Mabion SAINDUSTRY | 7 | Oct 25, 2023 | clinicaltrials |
| NCT04091503 | Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma | completed | Phase 1 | 30 | Center Trials & Treatment EuropeNETWORK | 3 | Apr 25, 2023 | clinicaltrials |
| NCT05622058 | A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer | terminated | Phase 1 | 6 | Aileron Therapeutics, Inc.INDUSTRY | 4 | Feb 27, 2023 | clinicaltrials |
| NCT02420821 | A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)(IMmotion151) | completed | Phase 3 | 915 | Hoffmann-La RocheINDUSTRY | 21 | Jan 30, 2023 | clinicaltrials |
| NCT04022876 | A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) | terminated | Phase 1 | 35 | Aileron Therapeutics, Inc.INDUSTRY | 7 | Oct 10, 2022 | clinicaltrials |
| NCT01265849 | Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity(IT-MATTERS) | completed | Phase 3 | 928 | CEL-SCI CorporationINDUSTRY | 23 | Aug 19, 2022 | clinicaltrials |
| NCT02162667 | Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer | completed | Phase 3 | 562 | CelltrionINDUSTRY | 22 | Aug 3, 2022 | clinicaltrials |
| NCT05485259 | Effect of Alpha-lipoic Acid on Regression of Low-grade Squamous Intraepithelial Lesions (LSIL) | completed | N/A | 100 | University of ZagrebOTHER | 2 | Aug 3, 2022 | clinicaltrials |
| NCT04176757 | A Study of ZN-c5 in Participants With Breast Cancer | completed | Phase 1 | 35 | Zeno Alpha Inc.INDUSTRY | 3 | Aug 1, 2022 | clinicaltrials |
| NCT02425891 | A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) | completed | Phase 3 | 902 | Hoffmann-La RocheINDUSTRY | 40 | Jul 19, 2022 | clinicaltrials |
| NCT02340221 | A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy(SANDPIPER) | terminated | Phase 3 | 631 | Hoffmann-La RocheINDUSTRY | 28 | Jul 12, 2022 | clinicaltrials |
| NCT00976911 | AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer | completed | Phase 3 | 361 | Hoffmann-La RocheINDUSTRY | 14 | Jun 21, 2022 | clinicaltrials |
| NCT00920816 | Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer | completed | Phase 3 | 492 | PfizerINDUSTRY | 14 | May 6, 2022 | clinicaltrials |
| NCT05301985 | Preoperative Administration of Oral Carbohydrate Drink, Neutrophil/Lymphocyte Ratio and Postoperative Complications | completed | N/A | 60 | Nermina RizvanovićOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT04633564 | MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC | completed | Phase 3 | 671 | Mylan Pharmaceuticals IncINDUSTRY | 17 | Mar 16, 2022 | clinicaltrials |
| NCT02810457 | Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer(AVANA) | completed | Phase 3 | 731 | Centus Biotherapeutics LimitedINDUSTRY | 24 | Mar 10, 2022 | clinicaltrials |
| NCT00545129 | A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone | completed | Phase 2 | 59 | PfizerINDUSTRY | 13 | Jun 18, 2021 | clinicaltrials |
| NCT01566721 | A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer(SafeHER) | completed | Phase 3 | 2,577 | Hoffmann-La RocheINDUSTRY | 59 | Apr 27, 2021 | clinicaltrials |
| NCT00830180 | Open Label Extension In Cancer Patients | completed | Phase 2 | 41 | PfizerINDUSTRY | 10 | Apr 5, 2021 | clinicaltrials |
| NCT01739764 | An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol | completed | Phase 4 | 215 | Hoffmann-La RocheINDUSTRY | 25 | Jan 7, 2021 | clinicaltrials |
| NCT02631876 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer(FORWARD I) | completed | Phase 3 | 366 | ImmunoGen, Inc.INDUSTRY | 13 | Oct 14, 2020 | clinicaltrials |
| NCT00625898 | BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab(BETH) | terminated | Phase 3 | 3,509 | NSABP Foundation IncNETWORK | 40 | Sep 10, 2020 | clinicaltrials |
| NCT02031458 | A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer(BIRCH) | completed | Phase 2 | 667 | Hoffmann-La RocheINDUSTRY | 19 | Jan 6, 2020 | clinicaltrials |
Data updated 19 days agoSource updated unknownsource: clinicaltrials